To date, five successful and one partial response cases of FH-mutated pRCC treated with first-line ipilimumab plus nivolumab and one successful case of HLRCC FH-mutated pRCC treated with first-line pembrolizumab have been reported21–24. This evidence concerns the gene FH and hereditary leiomyomatosis and renal cell cancer.